Abstract:BACKGROUND:Amyloid β (Aβ) accumulates in Alzheimer's disease (AD) brain. Microglial activation also occurs in AD, and this inflammatory response may contribute to disease progression. Microglial activation can be induced by Aβ, but the mechanisms by which this occurs have not been defined. The nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1) regulates microglial activation in response to several stimuli through its interactions with the transcription factor, NF-κB. The purpose of this study was to evaluate whether PARP-1 activation is involved in Aβ-induced microglial activation, and whether PARP-1 inhibition can modify microglial responses to Aβ.METHODS:hAPP(J20) mice, which accumulate Aβ with ageing, were crossed with PARP-1(-/-) mice to assess the effects of PARP-1 depletion on microglial activation, hippocampal synaptic integrity, and cognitive function. Aβ peptide was also injected into brain of wt and PARP-1(-/-) mice to directly determine the effects of PARP-1 on Aβ-induced microglial activation. The effect of PARP-1 on Aβ-induced microglial cytokine production and neurotoxicity was evaluated in primary microglia cultures and in microglia-neuron co-cultures, utilizing PARP-1(-/-) cells and a PARP-1 inhibitor. NF-κB activation was evaluated in microglia infected with a lentivirus reporter gene.RESULTS:The hAPP(J20) mice developed microglial activation, reduced hippocampal CA1 calbindin expression, and impaired novel object recognition by age 6 months. All of these features were attenuated in hAPP(J20)/PARP-1(-/-) mice. Similarly, Aβ(1-42) injected into mouse brain produced a robust microglial response in wild-type mice, and this was blocked in mice lacking PARP-1 expression or activity. Studies using microglial cultures showed that PARP-1 activity was required for Aβ-induced NF-κB activation, morphological transformation, NO release, TNFα release, and neurotoxicity. Conversely, PARP-1 inhibition increased release of the neurotrophic factors TGFβ and VEGF, and did not impair microglial phagocytosis of Aβ peptide.CONCLUSIONS:These results identify PARP-1 as a requisite and previously unrecognized factor in Aβ-induced microglial activation, and suggest that the effects of PARP-1 are mediated, at least in part, by its interactions with NF-κB. The suppression of Aβ-induced microglial activation and neurotoxicity by PARP-1 inhibition suggests this approach could be useful in AD and other disorders in which microglial neurotoxicity may contribute.

Poly (ADP-ribose) polymerase 1 inhibition prevents neurodegeneration and promotes α-synuclein degradation via transcription factor EB-dependent autophagy in mutant α-synucleinA53T model of Parkinson's disease

[Poly Adenosine Diphosphate-Ribosylation and Neurodegenerative Diseases].

Poly(ADP-ribose) drives pathologic α-synuclein neurodegeneration in Parkinson’s disease

PAR2-mediated epigenetic upregulation of α-synuclein contributes to the pathogenesis of Parkinson׳s disease.

Poly (ADP-ribose) polymerase 1 and neurodegenerative diseases: past, present, and future

PARP1 promotes NLRP3 activation via blocking TFEB-mediated autophagy in rotenone-induced neurodegeneration

Endothelial LRP1-ICD Accelerates Cognition-Associated Alpha-Synuclein Pathology and Neurodegeneration through PARP1 Activation in a Mouse Model of Parkinson’s Disease

Inhibition of Abnormal C/EBPβ/α‐Syn Signaling Pathway Through Activation of Nrf2 Ameliorates Parkinson's Disease‐like Pathology

Leucine Carboxyl Methyltransferase Downregulation and Protein Phosphatase Methylesterase Upregulation Contribute Toward the Inhibition of Protein Phosphatase 2A by α-Synuclein

Inhibition of EHMT1/2 rescues synaptic damage and motor impairment in a PD mouse model

Nuclear poly(ADP-ribose) activity is a therapeutic target in amyotrophic lateral sclerosis

The advance of poly ADP-ribose polymerase-1 and poly ADP-ribose polymerase-1-dependent cell death in nervous system diseases

Curcumin Ameliorates the Neurodegenerative Pathology in A53T α-synuclein Cell Model of Parkinson’s Disease Through the Downregulation of mTOR/p70S6K Signaling and the Recovery of Macroautophagy

Poly(ADP-ribose)polymerase-1 Modulates Microglial Responses to Amyloid Β

The role of PARP1 in neurodegenerative diseases and aging

PDCD4 Triggers Α-Synuclein Accumulation and Motor Deficits Via Co-Suppressing TFE3 and TFEB Translation in a Model of Parkinson’s Disease

In vitro modulation of mTOR and mGlur5 influence α-synuclein accumulation

Retinoic Acid Prevents α-Synuclein Preformed Fibrils-Induced Toxicity via Inhibiting STAT1-PARP1 Signaling

Polydatin Protects SH-SY5Y in Models of Parkinson's Disease by Promoting Atg5-mediated but Parkin-Independent Autophagy.

PAAN/MIF nuclease inhibition prevents neurodegeneration in Parkinson’s disease

Blocking the Self‐Destruct Program of Dopamine Neurons through Macrophage Migration Inhibitory Factor Nuclease Inhibition